Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02577250 · ClinicalTrials.gov registry record · Phase 1
Ketamine Infusions for PTSD and Treatment-Resistant Depression
A Phase 1 study, sponsored by Minneapolis Veterans Affairs Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02577250 is a Phase 1 study that has completed, run by Minneapolis Veterans Affairs Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT02577250, a Phase 1 study, has completed, sponsored by Minneapolis Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning. Veterans with both depression and PTSD have been shown to be at much higher risk of suicide than individuals with only one of these disorders. Ketamine has been shown to have rapid antidepressant effects and also therapeutic action over PTSD symptoms. The purpose of this study is to see whether ketamine, when given as repeated infusions, can produce quick and sustained improvement in depression and PTSD symptoms for individuals who have not had their symptoms effectively treated by current treatments.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02577250
The ClinicalTrials.gov registry entry for NCT02577250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Veterans Affairs Medical Center, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT02577250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02577250 about?
NCT02577250 is a clinical study titled "Ketamine Infusions for PTSD and Treatment-Resistant Depression". The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning. Veterans with both depression and PTSD have been shown to be at much higher risk of suicide t...
What is the current status of trial NCT02577250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-05. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02577250?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT02577250?
This trial is sponsored by Minneapolis Veterans Affairs Medical Center, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.